2024 World Conference on Lung Cancer (WCLC) - Posters-P4.17D.06 Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System

P4.17D.06 Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System

Back to course

Pdf Summary

The Pan-Canadian Lung Cancer Observational Study (PALEOS) is a multicenter, ambispective observational study focusing on lung cancer patients across Canada. PALEOS aims to provide real-world evidence (RWE) regarding the epidemiology, natural history, treatment patterns, and outcomes of lung cancer, thereby supporting healthcare decision-making and patient advocacy.<br /><br />Initiated to address gaps in randomized controlled trials, PALEOS leverages data from the healthieTM RWD platform, capturing detailed patient information across the cancer treatment spectrum. With an ambitious recruitment goal of 25,000 patients over 20 years, the study covers both urban and rural populations of Canada and is expanding to include sites in the US.<br /><br />The study's primary objective is to document the treatment patterns and natural history of lung cancer since 2000 using retrospective and prospective data. Secondary goals include evaluating patient-reported outcomes and understanding the spread of metastatic cancer in various subgroups. The study also aims to track the adoption of new diagnostic tests and treatments and compare the history and outcomes of patients with rare molecular tumor subtypes.<br /><br />Results to date show exponential recruitment growth, with 1,900 new cases in 2024 compared to 69 in 2020. PALEOS reports a median diagnosis age of 69 years, predominantly late-stage cancer (54% diagnosed at stage IV), and frequent use of immunotherapy as a first-line treatment. The study also reveals significant use of molecular biomarker testing with notable findings such as EGFR mutations.<br /><br />The study anticipates further growth in the number of participating sites and continued exploration of artificial intelligence technology to enhance data analysis. PALEOS serves as a robust platform for future clinical trials and health technology assessments, aiming to improve lung cancer care and patient outcomes.

Asset Subtitle

Sara Kuruvilla

Meta Tag

Speaker Sara Kuruvilla

Topic Global Health, Health Services & Health Economics

Keywords

PALEOS

lung cancer

observational study

real-world evidence

treatment patterns

healthcare decision-making

patient advocacy

molecular biomarker testing

immunotherapy

artificial intelligence